Cardiometabolic Multimorbidity in Older Adults: Risk Assessment, Individualised Treatment, and Evidence Gaps
Cardiometabolic multimorbidity, encompassing combinations of hypertension, diabetes, dyslipidaemia, obesity, and cardiovascular disease, is highly prevalent in older adults and drives excess mortality, disability, and healthcare utilisation. Yet, older adults—especially those ≥75 years with frailty, multimorbidity, or cognitive impairment—remain underrepresented in pivotal cardiometabolic randomised trials, limiting the applicability of current risk scores, treatment thresholds, and guideline recommendations to geriatric patients. This narrative review synthesises the contemporary evidence on cardiometabolic medicine in older adults, highlighting the gaps in epidemiology, risk stratification, therapeutic decision-making, and patient-centred outcomes. Emerging data confirm that the clustering of cardiometabolic risk factors is associated with steeply increased risks of sudden cardiac death, heart failure, and all-cause mortality in ageing populations, but robust intervention trials targeting these clusters in older, frail individuals are scarce. Furthermore, evidence for newer pharmacologic agents (such as SGLT2 inhibitors, GLP-1 receptor agonists, and PCSK9 inhibitors) in the oldest-old with functional impairment and polypharmacy is limited, leading to wide practice variation and frequent extrapolation from younger cohorts. The review is structured thematically to address the following: the epidemiology and phenotypes of cardiometabolic multimorbidity in older adults; the limitations of existing risk models and guideline targets; challenges in balancing intensive treatment with risks of adverse events and functional decline; and the role of frailty, comorbidity, and patient preferences in clinical decision-making. Finally, it outlines research priorities, including pragmatic geriatric-focused trials, the incorporation of frailty and function into cardiometabolic guidelines, and the development of real-world registries, to inform individualised treatment and de-intensification strategies in this rapidly growing population.
Authors
- Marilena Giannoudi (ORCID: https://orcid.org/0000-0002-5771-7737)
- Christos Fragoulis (ORCID: https://orcid.org/0000-0001-5598-9950)
- Konstantinos P Tsioufis (ORCID: https://orcid.org/0000-0002-7636-6725)
- Vasileios Kordalis
- Vasiliki Katsi
Institutions
- University of Leeds (GB)
- National and Kapodistrian University of Athens (GR)
- Aristotle University of Thessaloniki (GR)
- Hippocration General Hospital (GR)
Publication Details
- Journal
- Journal of Clinical Medicine
- Published
- 2026-11-20
- DOI
- https://doi.org/10.3390/jcm15229115
- Primary Topic
- Chronic Disease Management Strategies
- Type
- article
- Field-Weighted Citation Impact
- 0.00